论文部分内容阅读
1 文献来源rn研究一:Hellmann MD,Ciuleanu TE,Pluzanski A,et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med,2018,378(22):2093-2104.